share_log

Teva Pharmaceutical Industries (NYSE:TEVA) Climbs 5.3% This Week, Taking Five-year Gains to 117%

Teva Pharmaceutical Industries (NYSE:TEVA) Climbs 5.3% This Week, Taking Five-year Gains to 117%

梯瓦制药(纽交所:TEVA)本周上涨5.3%,五年涨幅达117%。
Simply Wall St ·  07/17 13:13

When you buy a stock there is always a possibility that it could drop 100%. But on the bright side, you can make far more than 100% on a really good stock. Long term Teva Pharmaceutical Industries Limited (NYSE:TEVA) shareholders would be well aware of this, since the stock is up 117% in five years. It's also good to see the share price up 26% over the last quarter. But this could be related to the strong market, which is up 13% in the last three months.

购买股票时总会有可能跌幅达100%以上。但美好的是,您在好股票上可以获得比100%更高的收益。长期持有梯瓦制药(NYSE:TEVA)的股东应该已经知道这一点,因为股票已经上涨了117%,达到5年。在过去的一个季度里,股价上涨了26%,这也是一件好事。但这可能与市场强劲有关,过去三个月市场上涨了13%。

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

在过去的一周之内,获得的强劲收益是否表明了长期回报受到基本面的推动值得关注。

Teva Pharmaceutical Industries isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

梯瓦制药目前没有盈利,因此大多数分析师会查看营业收入增长情况,以了解基础业务增长的速度。一般来说,没有盈利的公司每年都有望增加营收,而且速度还不错。可以想象,快速的营收增长如果持续下去,通常会导致快速的利润增长。

In the last 5 years Teva Pharmaceutical Industries saw its revenue shrink by 2.5% per year. Given that scenario, we wouldn't have expected the share price to rise 17% per year, but that's what it did. It just goes to show tht the market is forward looking, and it's not always easy to predict the future based on past trends. Still, this situation makes us a little wary of the stock.

在过去的5年里,梯瓦制药的营业收入年均下降2.5%。在这种情况下,我们不会预期股价每年上涨17%,但事实确实如此。这只是表明市场是前瞻性的,并且仅依靠过去的趋势并不总是容易预测未来。尽管如此,这种情况让我们对该股持谨慎态度。

The graphic below depicts how earnings and revenue have changed over time (unveil the exact values by clicking on the image).

下面的图表显示了收益和营收随时间的变化情况(通过单击图像揭示确切的值)。

big
NYSE:TEVA Earnings and Revenue Growth July 17th 2024
纽交所:TEVA收益和营收增长2024年7月17日

Teva Pharmaceutical Industries is a well known stock, with plenty of analyst coverage, suggesting some visibility into future growth. Given we have quite a good number of analyst forecasts, it might be well worth checking out this free chart depicting consensus estimates.

梯瓦制药是一支知名股票,受到许多分析师的关注,这表明市场对未来增长有一定的预期。由于我们有相当数量的分析师预测,因此检查这个免费图表描绘的共识估计可能非常值得。

A Different Perspective

不同的观点

It's nice to see that Teva Pharmaceutical Industries shareholders have received a total shareholder return of 105% over the last year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 17% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. Shareholders might want to examine this detailed historical graph of past earnings, revenue and cash flow.

很高兴看到梯瓦制药股东在过去一年中获得了总股东回报率达105%。由于一年的TSR(股东回报率)优于五年的TSR(后者达到每年17%),因此似乎该股票的表现近期有所改善。在最好的情况下,这可能暗示了一些真正的业务势头,这意味着现在可能是深入研究的好时机。股东可能希望检查过去收益,营业收入和现金流的详细历史图表。

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of companies that have proven they can grow earnings.

如果您愿意查看另一家公司(具有潜在的更好财务状况),请不要错过这个免费的公司列表,证明它们可以增长收益。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文所引述的市场回报反映了目前在美国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对本文有反馈?对内容感到担忧?请直接与我们联系。或者,发送电子邮件至editorial-team@simplywallst.com。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发